Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
Amid increasing reports of monkeypox infections primarily in Europe and the US, Japan is developing vaccine and therapeutic plans to deal with a possible outbreak on its own soil, with a clinical research program launched for the smallpox drug TPOXX…
To read the full story
Related Article
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- Japan Confirms 1st Monkeypox Case
July 26, 2022
- KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
July 25, 2022
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…